Spondyloarthropathies News

The FDA has approved the second biosimilar to etanercept, etanercept-ykro, for all eligible indications of the biologic product, according to an FDA press release.

Approximately 58% of patients in clinical remission after taking infliximab for ankylosing spondylitis relapse within 12 months after discontinuing the treatment, according to data published in Arthritis Research & Therapy.

CHICAGO — Rheumatologists should make greater efforts to collaborate with ophthalmologists to better care for patients with inflammatory and systemic eye diseases such as uveitis and scleritis, according to Jim T. Rosenbaum, MD, chief of the division of arthritis and rheumatic diseases at Oregon Health & Science University.

The FDA has approved Cimzia for the treatment of adults with nonradiographic axial spondyloarthritis with objective signs of inflammation, making it the first ever medication approved for the condition, according to a press release.

Primary care patients with inflammatory disease, particularly those with early-onset disease, demonstrate elevated rates of depression and anxiety, according to data published in the Annals of the Rheumatic Diseases.

The addition of certolizumab pegol to background medication for nonradiographic axial spondyloarthritis is superior to adding placebo, according to study results in Arthritis & Rheumatology.

Patients with ankylosing spondylitis demonstrate an increased risk for venous thromboembolism, particularly in the first year after diagnosis, according to findings published in the Annals of the Rheumatic Diseases.

LAS VEGAS — Dislocations after total hip arthroplasty in patients with ankylosing spondylitis were infrequent and less than anticipated at 20-year follow-up, according to a presenter here at the American Academy of Orthopaedic Surgeons Annual Meeting.

Faced with an increasing incidence and prevalence of autoimmune disease in the United States —approximately 23.5 million Americans are affected across the country, according to the NIH — Bonnie Feldman, MBA, DDS, says it is time to acknowledge what she calls “an invisible epidemic.”

Reduced doses of TNF inhibitor therapy were noninferior to full doses in maintaining low-disease activity after 1 year in a cohort of patients with ankylosing spondylitis, according to data published in Arthritis Research & Therapy.